Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxifloxacin vs. Ofloxacin for bacterial conjunctivitis in Chinese patients
NCT01573910Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- May 2012
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Moxisurge in bacterial conjunctivitis (BC) (2 arms), sponsored by Alcon Inc. Primary endpoints: Clinical Cure Rate at 9 days and Microbiological Success Rate at 9 days. Started May 2012; status: completed.
02
Drugs
Moxisurge
03
Conditions
bacterial conjunctivitis (BC)
Beyond the preview
Go deeper on NCT01573910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01573910.